Lv51
820 积分 2025-05-07 加入
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
2小时前
待确认
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial
2小时前
已完结
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
21天前
已完结
Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator
25天前
已完结
Immunodeficiency-associated lymphomas
25天前
已完结
Stromal gene signatures in large-B-cell lymphomas
25天前
已完结
Stromal gene signatures in large-B-cell lymphomas
25天前
已关闭
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma
29天前
已完结
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
29天前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
29天前
已完结
皖公网安备34019202002308
